(Q43446878)

23 November 2017

title

Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem (English)

1 reference

23 November 2017

main subject

Pseudomonas aeruginosa

1 reference

Yoshinori Yamano

1

1 reference

23 November 2017

Toru Nishikawa

2

1 reference

23 November 2017

Takaji Fujimura

3

1 reference

23 November 2017

Takashi Yutsudou

4

1 reference

23 November 2017

Masakatsu Tsuji

5

1 reference

23 November 2017

Hideaki Miwa

6

1 reference

23 November 2017

language of work or name

1 reference

1 December 2006

1 reference

The Journal of Antibiotics

23 November 2017

published in

1 reference

23 November 2017

volume

59

1 reference

23 November 2017

issue

12

1 reference

23 November 2017

page(s)

791-796

1 reference

https://scigraph.springernature.com/pub.10.1038/ja.2006.104

23 November 2017

exact match

0 references

cites work

Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa: active efflux as a contributing factor to beta-lactam resistance

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

PER-1 is still widespread in Turkish hospitals among Pseudomonas aeruginosa and Acinetobacter spp.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

PER-1 beta-lactamase-producing Pseudomonas aeruginosa in an intensive care unit

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Multifocal detection of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase in Northern Italy

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Multidrug-resistant Pseudomonas aeruginosa producing PER-1 extended-spectrum serine-beta-lactamase and VIM-2 metallo-beta-lactamase.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Synthesis and modification of a novel 1 beta-methyl carbapenem antibiotic, S-4661

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

In vitro antimicrobial activity of doripenem, a new carbapenem

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

A DIRECT SPECTROPHOTOMETRIC ASSAY FOR PENICILLIN BETA-LACTAMASE (PENICILLINASE)

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Comparative pharmacokinetics of the carbapenems: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

High Prevalence of PER-1 Extended-Spectrum β-Lactamase-Producing Acinetobacter spp. in Korea

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

PER-1- and OXA-10-like beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential

1 reference

https://api.crossref.org/works/10.1038%2FJA.2006.104

7 January 2021

Identifiers

DOI

10.1038/JA.2006.104

1 reference

23 November 2017

1 reference